Publication Name	World Journal of Clinical Oncology
Manuscript ID	91968
Country	Spain

Received	2024-01-11 08:44
Peer-Review Started	2024-01-11 08:44
To Make the First Decision
Return for Revision	2024-04-18 19:28
Revised	2024-04-28 07:48
Second Decision	2024-05-17 02:44
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-05-17 07:20
Articles in Press	2024-05-17 07:20
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-05-30 09:16
Publish the Manuscript Online	2024-07-16 06:17

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Editorial
Article Title	Neoadjuvant treatment of rectal cancer: Where we are and where we are going
Manuscript Source	Invited Manuscript
All Author List	Elísabet González Del Portillo, Felipe Couñago and Fernando López-Campos
ORCID	Author(s) ORCID Number Elísabet González Del Portillo http://orcid.org/0000-0002-0758-8156 Felipe Couñago http://orcid.org/0000-0001-7233-0234 Fernando López-Campos http://orcid.org/0000-0002-4077-0507
Funding Agency and Grant Number
Corresponding Author	Felipe Couñago, MD, PhD, Doctor, Doctor, Department of Radiation Oncology, GenesisCare Madrid, Modesto La Fuente, Madrid 28010, Spain. fcounago@gmail.com
Key Words	Locally advanced rectal cancer; Total neoadyuvant treatment; Radiotherapy; Biomarker; Magnetic resonance imaging; Conservative organ strategy; Watch and wait
Core Tip	The treatment of rectal cancer is well-established, based on total neoadjuvant treatment followed by deferred surgery. However, the development of biomarkers is necessary to predict which patients will achieve a complete pathological response and, therefore, may not require surgical treatment. The advent of new imaging techniques and their morphological, metabolic, and functional information pave the way for defining criteria for patients with locally advanced rectal cancer who are candidates for a conservative strategy.
Publish Date	2024-07-16 06:17
Citation	<p>González Del Portillo E, Couñago F, López-Campos F. Neoadjuvant treatment of rectal cancer: Where we are and where we are going. <i>World J Clin Oncol</i> 2024; 15(7): 790-795</p>
URL	https://www.wjgnet.com/2218-4333/full/v15/i7/790.htm
DOI	https://dx.doi.org/10.5306/wjco.v15.i7.790

Full Article (PDF)	WJCO-15-790-with-cover.pdf
Manuscript File	91968_Auto_Edited-YJP.docx
Answering Reviewers	91968-answering-reviewers.pdf
Audio Core Tip	91968-audio.m4a
Conflict-of-Interest Disclosure Form	91968-conflict-of-interest-statement.pdf
Copyright License Agreement	91968-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	91968-non-native-speakers.pdf
Peer-review Report	91968-peer-reviews.pdf
Scientific Misconduct Check	91968-scientific-misconduct-check.jpg
Scientific Editor Work List	91968-scientific-editor-work-list.pdf
CrossCheck Report	91968-crosscheck-report.pdf